Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir

Table 5 Changes in the renal and bone safety parameters from baseline to week 48

Variable	ETV group (n = 30)	TAF group (n = 30)	P value
eGFR (mL/min/1.73 m2)	-1.3 ± 3.2	-1.5 ± 2.9	0.76
Serum creatinine (μmol/L)	1.7 ± 5.6	2.1 ± 4.8	0.67
UPCR (mg/mmol)	-0.2 ± 0.6	-0.1 ± 0.5	0.58
BMD at lumbar spine (%)	-2.1 ± 1.4	-0.8 ± 1.2	0.004
BMD at hip (%)	-1.8 ± 1.3	-0.6 ± 1.1	0.007
Serum calcium (mmol/L)	-0.01 ± 0.05	-0.02 ± 0.04	0.42
Serum phosphate (mmol/L)	-0.03 ± 0.12	-0.04 ± 0.11	0.69
Serum alkaline phosphatase (U/L)	-3.7 ± 12.4	-4.3 ± 11.6	0.79
Serum parathyroid hormone (pg/mL)	-2.4 ± 8.7	-3.1 ± 9.2	0.68

Data are presented as mean ± standard deviation. ETV: Entecavir; TAF: Tenofovir alafenamide; BMD: Bone mineral density; eGFR: Estimated glomerular filtration rate; UPCR: Urine protein-to-creatinine ratio.